Florence JOLY

Université de Caen

SCHOLARLY PAPERS

4

DOWNLOADS

113

TOTAL CITATIONS

0

Scholarly Papers (4)

Actions:
Email selected abstracts
1.

Pharmacogenomic Predictor of Long-Term Residual Chemotherapy-Induced Peripheral Neuropathy in Ovarian Cancer Survivors: A Substudy of the GINECO Vivrovaire Study

Number of pages: 23 Posted: 03 Mar 2024
Morgan Zenatri, Tanguy Perennec, Clémence Michon, François Gernier, Jean-Michel Grellard, François-Xavier Piloquet, Coraline Dubot-Poitelon, Elsa Kalbacher, Olivier Tredan, Paule Augereau, Patricia Pautier, Luc Fey, Florence JOLY and Jean Sebastien Frenel
Institut de Cancerologie de l’Ouest, Institut de Cancerologie de l’Ouest, Institut de Cancerologie de l’Ouest, Centre François Baclesse, Centre François Baclesse, Institut de Cancerologie de l’Ouest, Université de Caen, Université de Bourgogne - CHRU de Besançon, University of Claude Bernard Lyon 1 - Medical Oncology Department, Institut de Cancerologie de l’Ouest, Gustave Roussy, Institut de Cancerologie de l’Ouest, Université de Caen and Institut de Cancérologie de l’Ouest Pays de Loire
Downloads 44 (913,720)

Abstract:

Loading...

ovarian cancer, long term survivors, chemotherapy-induced peripheral neuropathy, single nucleotide polymorphism, pharmacogenomic, patient-reported outcome

2.

Early Clinical and Molecular Biomarkers in Advanced Ovarian Cancer Patients Undergoing Neoadjuvant Chemotherapy: Chiva Phase Ii Gineco Trial

Number of pages: 22 Posted: 07 Oct 2024
Felix Blanc-Durand, Yahia Adnani, Benoit You, Gaetan De Rauglaudre, Isabelle-Laure Ray-Coquard, Pierre Combe, Cyril Abdeddaim, Florence JOLY, Gwenael Ferron, Clotilde Deldycke, Olivier Colomban, Marie Christine Kaminsky, Jerome Meunier, Jerome Alexandre, Coriolan L. Lebreton, Laurence Venat, Laure Favier, Christophe Louvet, Sophie Abadie-Lacourtoisie, Eric Pujade-Lauraine, Laure Chardin, Catherine Genestie, Pierre Alexandre Just, Etienne Rouleau and Alexandra Leary
University of Paris-Saclay - Institut Gustave Roussy, University of Paris-Saclay - Institut Gustave Roussy, Université Lyon 1 - Faculty of Medicine Lyon-Sud, affiliation not provided to SSRN, University of Claude Bernard Lyon 1 - Medical Oncology Department, affiliation not provided to SSRN, University of Lille II - Centre Oscar Lambret, Université de Caen, Institut Claudius Regaud, affiliation not provided to SSRN, Université Lyon 1 - Faculty of Medicine Lyon-Sud, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, University of Bordeaux - Institut Bergonié, University of Limoges - CHU Limoges, affiliation not provided to SSRN, Institut Mutualiste Montsouris, Western Cancer Institute, ARCAGY-GINECO, Gustave Roussy, Gustave Roussy, affiliation not provided to SSRN, Gustave Roussy and Université Paris XI Sud - Gustave Roussy Cancer Campus
Downloads 30 (1,055,809)

Abstract:

Loading...

Ovarian cancer, neoadjuvant chemotherapy, biomarkers, homologous recombination deficiency, TILS

3.

Adverse Events in the Placebo Arm of Solo2/Engot-Ov21 Maintenance Trial of Olaparib in Recurrent Ovarian Cancer

Number of pages: 27 Posted: 24 Sep 2024 Last Revised: 01 May 2025
Katherine Elizabeth Francis, Sandy Simon, Val Gebski, Florence JOLY, Jonathan A. Ledermann, Richard T. Penson, Amit Oza, Jacob Korach, Nuria Lainez, Sabrina Chiara Cecere, Giulia Tasca, Martina Gropp-Meier, Keiichi Fujiwara, Elizabeth S. Lowe, Michael Friedlander, Eric Pujade-Lauraine and Chee Khoon Lee
The University of Sydney, The University of Sydney, The University of Sydney - NHMRC Clinical Trials Centre, Université de Caen, University College London - UCL Cancer Institute, Harvard University - Harvard Medical School, University of Toronto - University Health Network, Tel Aviv University, affiliation not provided to SSRN, Istituto Nazionale Tumori - IRCCS Fondazione G. Pascale - Uro-Gynecological Medical Oncology, affiliation not provided to SSRN, affiliation not provided to SSRN, Saitama Medical University International Medical Center (SIMC), affiliation not provided to SSRN, affiliation not provided to SSRN, ARCAGY-GINECO and The University of Sydney
Downloads 22 (1,151,571)

Abstract:

Loading...

Placebo, adverse events, trial design, ovarian cancer, maintenance therapy, PARPi

4.

Efficacy of Secondary Cytoreductive Surgery for Relapsed Ovarian Low-Grade Serous Carcinoma: A Multicenter Analysis from French Tmrg Network

Number of pages: 27 Posted: 21 Apr 2025
Thomas Gaillard, Thomas Gaillard, Judicael Hotton, Enora Laas, Frederic Marchal, Cécile Loaec, Pierre-Emmanuel Colombo, Gwenael Ferron, Anne-Sophie Bats, Sebastien Gouy, Claire Bonneau, Floriane Jochum, Frédéric Guyon, Florence JOLY, Christophe Pomel, Dominique Berton-Ruigaud, Navid Mokarram-Dorri, Thibault De La Motte Rouge, Isabelle-Laure Ray-Coquard and Fabrice Lecuru
École Normale Supérieure - PSL Research University - Institut CurieInstitut Curie - Breast, Gynecology and Reconstructive Surgery Department, affiliation not provided to SSRN, PSL Research University - Institut Curie, affiliation not provided to SSRN, affiliation not provided to SSRN, University of Montpellier - Institute for Cancer Research in Montpellier, Institut Claudius Regaud, affiliation not provided to SSRN, Gustave Roussy, PSL Research University - Institut Curie, Université Paris Cité, University of Bordeaux - Institut Bergonié, Université de Caen, Centre Jean Perrin, affiliation not provided to SSRN, Aix-Marseille University - Institut Paoli-Calmettes, Institut Curie - Department of Medical Oncology, University of Claude Bernard Lyon 1 - Medical Oncology Department and PSL Research University - Institut Curie
Downloads 17 (1,212,741)

Abstract:

Loading...

Low-Grade Serous Ovarian Cancer, Secondary Cytoreductive Surgery, Recurrence, Progression-Free Survival, Overall Survival, Retrospective Study